Renalytix AI (GB:RENX) has released an update.
Renalytix AI, an AI-enabled in vitro diagnostics company, has announced plans to raise at least £10 million through new share issuances to accelerate its transition into commercial scale-up phase. The funds will be aimed at expanding sales, marketing, and customer service efforts to grow revenue and pursue profitability within the next two years. Additionally, the company is undergoing a debt restructuring and has appointed Julian Baines MBE as Executive Chairman.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.
